Roberto S Oliveri
Overview
Explore the profile of Roberto S Oliveri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillemanns P, Zikan M, Forget F, Denys H, Baurain J, Rob L, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39773564
Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the...
2.
Li T, Hiemstra I, Chiu C, Oliveri R, Elliott B, DeMarco D, et al.
Clin Pharmacol Ther
. 2022 Aug;
112(5):1108-1119.
PMID: 35996883
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion...
3.
Uccelli A, Laroni A, Ali R, Battaglia M, Blinkenberg M, Brundin L, et al.
Lancet Neurol
. 2021 Oct;
20(11):917-929.
PMID: 34687636
Background: Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory...
4.
Hutchings M, Mous R, Clausen M, Johnson P, Linton K, Chamuleau M, et al.
Lancet
. 2021 Sep;
398(10306):1157-1169.
PMID: 34508654
Background: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody...
5.
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi S, et al.
Trials
. 2019 May;
20(1):263.
PMID: 31072380
Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent...
6.
Gronhoj C, Jensen D, Vester-Glowinski P, Jensen S, Bardow A, Oliveri R, et al.
Int J Radiat Oncol Biol Phys
. 2018 Apr;
101(3):581-592.
PMID: 29678523
Background: Salivary gland hypofunction and xerostomia are major complications to head and neck radiotherapy. This trial assessed the safety and efficacy of adipose tissue-derived mesenchymal stem cell (ASC) therapy for...
7.
Fahrendorff M, Oliveri R, Johansson P
Scand J Trauma Resusc Emerg Med
. 2017 Apr;
25(1):39.
PMID: 28403868
Background: Management of the critically bleeding patient can be encountered in many medical and surgical settings. Common for these patients is a high risk of dying from exsanguination secondary to...
8.
Gronhoj C, Jensen D, Glovinski P, Jensen S, Bardow A, Oliveri R, et al.
Trials
. 2017 Mar;
18(1):108.
PMID: 28270226
Background: Salivary gland hypofunction and xerostomia are major complications following radiotherapy for head and neck cancer and may lead to debilitating oral disorders and impaired quality of life. Currently, only...
9.
Oliveri R, Bello S, Biering-Sorensen F
Neurobiol Dis
. 2013 Oct;
62:338-53.
PMID: 24148857
Traumatic spinal cord injury (SCI) is a devastating event with huge personal and societal costs. A limited number of treatments exist to ameliorate the progressive secondary damage that rapidly follows...
10.
Kolle S, Fischer-Nielsen A, Mathiasen A, Elberg J, Oliveri R, Glovinski P, et al.
Lancet
. 2013 Oct;
382(9898):1113-20.
PMID: 24075051
Background: Autologous fat grafting is increasingly used in reconstructive surgery. However, resorption rates ranging from 25% to 80% have been reported. Therefore, methods to increase graft viability are needed. Here,...